
    
      Open-label non-randomised phase Ib/II study conducted in two stages. Stage 1 will be dose
      escalation in a modified classical 6+6 design. Stage 2 will be an expansion cohort to gain
      additional information on safety and efficacy at the recommended phase II dose of
      acalabrutinib.
    
  